The diversity of HIV quasispecies within a single AIDS patient is far greater than the global diversity of influeneza annually, highlighting the enormous burden HIV imposes on the immune network. The capacity of HIV-1 to evolve quickly has significantly impaired our effort to produce effective vaccine and long lasting treatment strategy. This project utilizes multidisciplinary approaches to delineate determinants that drives the diversification of HIV-1.
Enhanced Expression Of The Epstein-Barr Virus Nuclear Antigen, EBNA1, As A Target For T-cell-Based Immunotherapy For Prevention Of Viral-Associated Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$356,513.00
Summary
Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be “immunologically silent” however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.